Elucid’s Lesion Inspection Tool Elevates Plaque Analysis

Elucid, a Boston-based AI medical tech company, has announced the commercial availability of its innovative Lesion Inspection Tool for coronary and carotid plaque analysis. Integrated into the Plaque-IQ software suite, this cutting-edge tool empowers physicians by providing detailed lesion-specific insights into plaque composition and burden, potentially transforming the assessment and management of coronary and carotid artery diseases.

Elucid’s latest tool propels Plaque-IQ, its state-of-the-art software for plaque analysis, into the spotlight. Unlike traditional methods that rely on population-based risk estimates, the Lesion Inspection Tool allows for precise quantification of individual plaque characteristics, such as lipid-rich necrotic core, offering a clearer picture of cardiovascular risk. With the support of CT-Virtual Histology™ technology, Plaque-IQ is trained and validated against ground truth histology, ensuring accuracy in diagnosing and managing high-risk plaque features linked to heart attacks and strokes. Dr. Jimmy Kerrigan, an interventional cardiologist, attests to the tool’s ability to enhance clinical decision-making by focusing on true disease biology, offering a personalized approach to treatment strategies.

By introducing the Lesion Inspection Tool, Elucid is setting a new standard in cardiovascular diagnostics. The capability to deliver actionable insights into lesion-specific plaque composition is poised to aid physicians in crafting pro-active, individualized care plans. As the first FDA-cleared algorithm of its kind, Elucid’s Plaque-IQ software is changing how clinicians approach atherosclerosis, prioritizing patient-specific treatment and ultimately improving cardiovascular outcomes.